Big Pharma Restructures Commercial Teams In India
Executive Summary
More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.
You may also be interested in...
India CEO Pay: Up, Up For Most, Eye On Gender Pay Gap As Women Execs Rise
C-suite remuneration at leading listed foreign and domestic drug firms in India rose in double digits for the most part in 2022-23, data compiled by Scrip show. While MDs/CEOs at domestic firms continue to take home sizeably higher earnings, the arrival of women leaders at the helm in some foreign firms puts the spotlight on gender pay parity.
Eisai Shrinks India Multiple Sclerosis Commercial Team
Eisai recalibrates sales and marketing efforts for Biogen’s multiple sclerosis portfolio in India, joining a growing list of foreign firms that appear to be rightsizing their commercial engine in an ultra-competitive market.
CEO Pay Mostly Up In India In Year Of C-Suite Exits
Most CEOs/MDs at leading listed foreign and domestic drug firms in India took home bigger pay packages in 2021-22, a period that also saw several top-level exits including at Abbott, Pfizer and Sanofi. Scrip examines some of the wider trends around executive compensation.